[225Ac]Ac-macropa-(T+P)-PEG6-DM1

N/A

Report date: 2025/11/06 13:43:27

Base Information

Drug Name[225Ac]Ac-macropa-(T+P)-PEG6-DM1
Drug Alias Name[225Ac]Ac-Macropa-trastuzumab-PEG6-DM1 ([225Ac]Ac-Macropa-T-PEG6-DM1) and [225Ac]Ac-Macropa-pertuzumab-PEG6-DM1 ([225Ac]Ac-Macropa-P-PEG6-DM1)[225Ac]Ac-Macropa-T-PEG6-DM1 + [225Ac]Ac-Macropa-P-PEG6-DM1 = [225Ac]Ac-Macropa-(T+P)-PEG6-DM1
ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Radiation-emitting products > Radioactive therapeutic agent +[4] 
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversite LavalUniversity Of Saskatchewan
China Registration ClassN/A

Develop Information

Active CompaniesUniversite LavalUniversity Of Saskatchewan
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A